Donepezil for dementia with Lewy bodies: meta‐analysis of multicentre, randomised, double‐blind, placebo‐controlled phase II, III, and, IV studies
2024

Donepezil for Dementia with Lewy Bodies: Meta-Analysis

Sample size: 312 publication Evidence: moderate

Author Information

Author(s): E. Mori, M. Ikeda, M. Ohdake

Primary Institution: Osaka University United Graduate School of Child Development

Hypothesis

What is the overall efficacy of donepezil on cognitive impairment and global clinical status in patients with dementia with Lewy bodies?

Conclusion

Donepezil shows overall efficacy in improving cognitive impairment and global clinical status in patients with dementia with Lewy bodies.

Supporting Evidence

  • Donepezil improved MMSE scores significantly compared to placebo.
  • The odds of improvement in CIBIC-plus were higher in the donepezil group.
  • Heterogeneity was found in NPI scores, affecting overall efficacy assessment.

Takeaway

This study found that a medicine called donepezil can help people with a type of dementia called Lewy body dementia think better and feel better overall.

Methodology

A meta-analysis of three randomized controlled trials comparing donepezil to placebo in patients with dementia with Lewy bodies.

Limitations

Heterogeneity in NPI scores among studies limited the overall efficacy assessment.

Participant Demographics

Participants were aged ≥50 years with mild to moderate-severe dementia, including both males and females.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI, 0.67–2.34 for MMSE; 95% CI, 1.13–4.26 for CIBIC-plus

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/psyg.13101

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication